A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Brivanib alaninate (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 03 Jul 2012 Planned number of patients changed from 125 to 130 as reported by European Clinical Trials Database.
- 03 May 2011 Status changed from active, no longer recruiting to completed.
- 03 May 2011 NCT reports status is completed, actual end date 1 Apr 2010, actual patient no. is 135.